These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 36481091)

  • 1. Qualitative analysis of telephonic comprehensive medication review content and delivery.
    Dhatt H; Vaffis S; Le D; Axon DR; Campbell PJ; Black H; Kolobova I; Nelson ML; Warholak T
    J Am Pharm Assoc (2003); 2023; 63(2):555-565. PubMed ID: 36481091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key informant perspectives about telephonic comprehensive medication review services in the United States.
    Anderson EJ; Dhatt H; Vaffis S; Nelson ML; Warholak T; Campbell PJ; Black H; Kolobova I; Axon DR
    J Am Pharm Assoc (2003); 2022; 62(3):817-825.e1. PubMed ID: 35067476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A checklist for a consistent, comprehensive medication review.
    Vaffis S; Dhatt H; Anderson E; Le D; Campbell PJ; Nelson M; Black H; Kolobova I; Axon DR; Warholak T
    J Am Pharm Assoc (2003); 2023; 63(5):1504-1507.e1. PubMed ID: 37394060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in telephonic comprehensive medication review in the United States from 2000 to present: a scoping literature review.
    Vaffis S; Dhatt H; Anderson EJ; Nelson M; Campbell P; Black H; Kolobova I; Warholak T
    J Am Pharm Assoc (2003); 2022; 62(2):406-412.e1. PubMed ID: 35067477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive medication review service by embedded pharmacists in primary care: Innovations and impact.
    Yoo A; Fennelly JE; Renauer MM; Coe AB; Choe HM; Marshall VD; Parsons D; Farris KB
    J Am Pharm Assoc (2003); 2022; 62(2):580-587.e1. PubMed ID: 34696978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of comprehensive medication reviews versus noncomprehensive medication review interventions and subsequent successful medication changes in a Medicare Part D population.
    Chinthammit C; Armstrong EP; Boesen K; Martin R; Taylor AM; Warholak T
    J Manag Care Spec Pharm; 2015 May; 21(5):381-9. PubMed ID: 25942999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting Medicare Part D beneficiaries' decision to receive comprehensive medication reviews.
    Doucette WR; Zhang Y; Chrischilles EA; Pendergast JF; Newland BA; Farris KB; Frank J
    J Am Pharm Assoc (2003); 2013; 53(5):482-7. PubMed ID: 24030125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Medication Reviews in Long-term Care Facilities: History of Process Implementation and 2015 Results.
    O'Shea TE; Zarowitz BJ; Erwin WG
    J Manag Care Spec Pharm; 2017 Jan; 23(1):22-26. PubMed ID: 28025922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social needs of dual-enrolled Medicare-Medicaid patients with medication nonadherence in a telehealth medication therapy management program.
    Almodóvar AS; Ross E; Nahata MC; Bingham JM
    J Manag Care Spec Pharm; 2023 Feb; 29(2):210-215. PubMed ID: 36705284
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of telephonic comprehensive medication reviews on patient outcomes.
    DeZeeuw EA; Coleman AM; Nahata MC
    Am J Manag Care; 2018 Feb; 24(2):e54-e58. PubMed ID: 29461851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide estimates of medication therapy management delivery under the Medicare prescription drug benefit.
    Pestka DL; Zillich AJ; Coe AB; Farris KB; Adeoye OA; Snyder ME; Farley JF
    J Am Pharm Assoc (2003); 2020; 60(3):456-461. PubMed ID: 31926872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management.
    Brummel A; Lustig A; Westrich K; Evans MA; Plank GS; Penso J; Dubois RW
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1152-8. PubMed ID: 25597053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies identified with the use of prescription claims and diagnostic billing data following a comprehensive medication review.
    Roane TE; Patel V; Hardin H; Knoblich M
    J Manag Care Pharm; 2014 Feb; 20(2):165-73. PubMed ID: 24456318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use.
    Almodovar AS; Axon DR; Coleman AM; Warholak T; Nahata MC
    J Manag Care Spec Pharm; 2018 May; 24(5):416-422. PubMed ID: 29694292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Clinical and Attitudinal Characteristics on Obtaining Comprehensive Medication Reviews.
    Farris KB; Salgado TM; Aneese N; Marshall VD; Pendergast JF; Frank J; Chrischilles EA; Doucette WR
    J Manag Care Spec Pharm; 2016 Apr; 22(4):388-95. PubMed ID: 27023692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Medication Review Completion in Medically Underserved Areas and Populations.
    Le LD; Paulk IR; Axon DR; Bingham JM
    J Health Care Poor Underserved; 2021; 32(3):1301-1311. PubMed ID: 34421032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive medication reviews by ward-based pharmacists in Swedish hospitals: What does the patient have to say?
    Kempen TGH; Kälvemark A; Gillespie U; Stewart D
    J Eval Clin Pract; 2020 Feb; 26(1):149-157. PubMed ID: 30834647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacists' and residents' decision making and unmet information needs when completing comprehensive medication reviews.
    McPherson KL; Adeoye-Olatunde OA; Osborne JM; Doucette WR; Gernant SA; Jaynes H; Phansalkar S; Russ-Jara AL; Snyder ME
    J Am Pharm Assoc (2003); 2020; 60(3S):S41-S50.e2. PubMed ID: 31987810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best Practices: Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management.
    Brummel A; Lustig A; Westrich K; Evans MA; Plank GS; Penso J; Dubois RW
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1152-8. PubMed ID: 25491911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining Medicare Part D Medication Therapy Management program in the context of mental health.
    Murugappan MN; Seifert RD; Farley JF
    J Am Pharm Assoc (2003); 2020; 60(4):571-579.e1. PubMed ID: 31953120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.